论文部分内容阅读
目的比较两种三联疗法根治幽门螺杆菌(Hp)的疗效及安全性。方法选择快速尿素酶及14C-尿素呼气试验确诊的80例Hp感染患者,随机分为两组,每组40例。其中雷贝拉唑组采用雷贝拉唑、克拉霉素、加替沙星三联方案;枸橼酸铋钾(CBS)组用枸橼酸铋钾(CBS)、克拉霉素、加替沙星三联方案。疗程结束4周后复查快速尿素酶及14C-尿素呼气试验。结果奥美拉唑组与枸橼酸铋钾组Hp根除率分别为93.33%(40/56)和75.00%(40/45),两种根除Hp的治疗方案比较差异有统计学意义(χ2=7.5664,P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论雷贝拉唑、克拉霉素、加替沙星三联疗法在两种方案中Hp根治率高,值得临床推广。
Objective To compare the efficacy and safety of two kinds of triple therapy in the treatment of Helicobacter pylori (Hp). Methods Eighty patients with Hp infection diagnosed by rapid urease and 14 C-urea breath test were randomly divided into two groups (n = 40 in each group). Rabeprazole group rabeprazole, clarithromycin, gatifloxacin triple program; bismuth potassium citrate (CBS) group with bismuth potassium citrate (CBS), clarithromycin, gatifloxacin Triple program. Four weeks after the end of treatment review rapid urease and 14 C-urea breath test. Results The eradication rates of Hp in omeprazole group and bismuth potassium citrate group were 93.33% (40/56) and 75.00% (40/45), respectively. There was significant difference between the two treatments of Hp eradication (χ2 = 7.5664, P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion Rabeprazole, clarithromycin, gatifloxacin triple therapy in the two programs Hp radical rate, worthy of clinical promotion.